AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Hormone therapy with estrogen and progestin does not appear to play a significant role in reducing the risk of developing colorectal cancer, according to a recent analysis of data from the Women's Health Initiative.
Hormone therapy (HT) was associated with a 44% reduction in the overall likelihood of developing colorectal cancer. But women who used HT during the study's average 5.6 years of follow-up had a significantly higher percentage of colorectal cancers with lymph node involvement (59.0% vs. 29.4%), a higher average number of positive nodes (3.2 vs. 0.8), and a more advanced stage at diagnosis (76.2% vs. 48.5%) than those women who were given placebo (N. Engl. J. Med. 350[10]:991-1004, 2004).
"Current data are insufficient to support the use of estrogen plus progestin to reduce the risk of colorectal cancer in any population," said Dr. Rowan T. Chlebowski of the Harbor--UCLA Research and Education Institute, Torrance, Calif., and his colleagues.
"These findings support wider implementation of bowel screening among postmenopausal women who are using hormone therapy," they said.
In the prospective study, invasive colorectal cancer ...
Source: HighBeam Research, Analysis of whi data: wider bowel screening needed in HT...